featured
Adaptive or Standard Radiotherapy for Stage III NSCLC According to [18F]FDG-PET Tumour Residual Uptake
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7-IFCT-1402): a multicentre, randomised, controlled phase 2 trial
Lancet Oncol 2024 Sep 01;25(9)1176-1187, P Vera, S Thureau, F Le Tinier, P Chaumet-Riffaud, S Hapdey, H Kolesnikov-Gauthier, E Martin, A Berriolo-Riedinger, N Pourel, JM Broglia, P Boissellier, S Guillemard, N Salem, I Brenot-Rossi, C Le Péchoux, C Berthold, E Giroux-Leprieur, D Moreau, S Guillerm, K Benali, L Tessonnier, C Audigier-Valette, D Lerouge, E Quak, C Massabeau, F Courbon, P Moisson, A Larrouy, R Modzelewski, P Gouel, N Ghazzar, A Langlais, E Amour, G Zalcman, P GiraudFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.